134 related articles for article (PubMed ID: 18314908)
1. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
[TBL] [Abstract][Full Text] [Related]
2. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
[TBL] [Abstract][Full Text] [Related]
3. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Vallon-Christersson J; Grabau D; Arason A; Gunnarsson H; Agnarsson BA; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R25. PubMed ID: 20459607
[TBL] [Abstract][Full Text] [Related]
4. Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer.
Jiang T; Shi W; Natowicz R; Ononye SN; Wali VB; Kluger Y; Pusztai L; Hatzis C
BMC Genomics; 2014 Oct; 15(1):876. PubMed ID: 25294321
[TBL] [Abstract][Full Text] [Related]
5. The
Makuch-Kocka A; Kocki J; Brzozowska A; Bogucki J; Kołodziej P; Płachno BJ; Bogucka-Kocka A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673050
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtyping of breast cancer: opportunities for new therapeutic approaches.
Mullan PB; Millikan RC
Cell Mol Life Sci; 2007 Dec; 64(24):3219-32. PubMed ID: 17957336
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a reliable DNA copy-number-based machine learning algorithm (CopyClust) for breast cancer integrative cluster classification.
Young CC; Eason K; Manzano Garcia R; Moulange R; Mukherjee S; Chin SF; Caldas C; Rueda OM
Sci Rep; 2024 May; 14(1):11861. PubMed ID: 38789621
[TBL] [Abstract][Full Text] [Related]
8. Structural and genic characterization of stable genomic regions in breast cancer: relevance to chemotherapy.
Park NI; Rogan PK; Tarnowski HE; Knoll JH
Mol Oncol; 2012 Jun; 6(3):347-59. PubMed ID: 22342187
[TBL] [Abstract][Full Text] [Related]
9. A systems approach to analysis of molecular complexity in breast cancer.
Hennessy BT; Gonzalez-Angulo AM; Carey MS; Mills GB
Clin Cancer Res; 2009 Jan; 15(2):417-9. PubMed ID: 19147744
[TBL] [Abstract][Full Text] [Related]
10. Functional exploration of copy number alterations in a Drosophila model of triple negative breast cancer.
Diaz JEL; Barcessat V; Bahamon C; Hecht C; Das TK; Cagan RL
Dis Model Mech; 2024 May; ():. PubMed ID: 38721669
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional analysis of 9p24 amplified genes in human breast cancer.
Wu J; Liu S; Liu G; Dombkowski A; Abrams J; Martin-Trevino R; Wicha MS; Ethier SP; Yang ZQ
Oncogene; 2012 Jan; 31(3):333-41. PubMed ID: 21666724
[TBL] [Abstract][Full Text] [Related]
12. NFIB is a potential target for estrogen receptor-negative breast cancers.
Moon HG; Hwang KT; Kim JA; Kim HS; Lee MJ; Jung EM; Ko E; Han W; Noh DY
Mol Oncol; 2011 Dec; 5(6):538-44. PubMed ID: 21925980
[TBL] [Abstract][Full Text] [Related]
13. The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
Shah SP; Roth A; Goya R; Oloumi A; Ha G; Zhao Y; Turashvili G; Ding J; Tse K; Haffari G; Bashashati A; Prentice LM; Khattra J; Burleigh A; Yap D; Bernard V; McPherson A; Shumansky K; Crisan A; Giuliany R; Heravi-Moussavi A; Rosner J; Lai D; Birol I; Varhol R; Tam A; Dhalla N; Zeng T; Ma K; Chan SK; Griffith M; Moradian A; Cheng SW; Morin GB; Watson P; Gelmon K; Chia S; Chin SF; Curtis C; Rueda OM; Pharoah PD; Damaraju S; Mackey J; Hoon K; Harkins T; Tadigotla V; Sigaroudinia M; Gascard P; Tlsty T; Costello JF; Meyer IM; Eaves CJ; Wasserman WW; Jones S; Huntsman D; Hirst M; Caldas C; Marra MA; Aparicio S
Nature; 2012 Apr; 486(7403):395-9. PubMed ID: 22495314
[TBL] [Abstract][Full Text] [Related]
14. Gene copy number variations in breast cancer of Sub-Saharan African women.
Ly M; Valent A; Diallo G; Penault-Lorca F; Dumke K; Marty V; Viehl P; Lazar V; Job B; Richon C; Scott V; Diallo DA; Bernaudin JF; Andre F
Breast; 2013 Jun; 22(3):295-300. PubMed ID: 22999459
[TBL] [Abstract][Full Text] [Related]
15. Novel treatment approaches for triple-negative breast cancer.
Telli ML; Ford JM
Clin Breast Cancer; 2010; 10 Suppl 1():E16-22. PubMed ID: 20587403
[TBL] [Abstract][Full Text] [Related]
16. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.
Turner N; Lambros MB; Horlings HM; Pearson A; Sharpe R; Natrajan R; Geyer FC; van Kouwenhove M; Kreike B; Mackay A; Ashworth A; van de Vijver MJ; Reis-Filho JS
Oncogene; 2010 Apr; 29(14):2013-23. PubMed ID: 20101236
[TBL] [Abstract][Full Text] [Related]
17. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
[TBL] [Abstract][Full Text] [Related]
19. Triple positive breast cancer: a distinct subtype?
Vici P; Pizzuti L; Natoli C; Gamucci T; Di Lauro L; Barba M; Sergi D; Botti C; Michelotti A; Moscetti L; Mariani L; Izzo F; D'Onofrio L; Sperduti I; Conti F; Rossi V; Cassano A; Maugeri-Saccà M; Mottolese M; Marchetti P
Cancer Treat Rev; 2015 Feb; 41(2):69-76. PubMed ID: 25554445
[TBL] [Abstract][Full Text] [Related]
20. Targeting triple negative breast cancer: is p53 the answer?
Turner N; Moretti E; Siclari O; Migliaccio I; Santarpia L; D'Incalci M; Piccolo S; Veronesi A; Zambelli A; Del Sal G; Di Leo A
Cancer Treat Rev; 2013 Aug; 39(5):541-50. PubMed ID: 23321033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
